Humacyte (NASDAQ:HUMA – Get Rating) had its target price lowered by investment analysts at Cowen from $8.00 to $5.00 in a research note issued to investors on Monday, The Fly reports. Cowen's price target would indicate a potential upside of 127.79% from the company's current price.

Other analysts also recently issued reports about the company. Piper Sandler reduced their target price on Humacyte to $2.75 in a research note on Wednesday, November 16th. BTIG Research cut their price target on Humacyte to $9.00 in a research note on Thursday, October 20th.

Humacyte Stock Performance

Shares of HUMA opened at $2.20 on Monday. The company has a debt-to-equity ratio of 0.37, a current ratio of 9.75 and a quick ratio of 9.75. The stock has a 50-day moving average of $3.14 and a 200-day moving average of $3.56. The company has a market cap of $226.34 million, a PE ratio of 6.86 and a beta of 0.92. Humacyte has a one year low of $2.18 and a one year high of $8.38.

Insider Buying and Selling at Humacyte

In related news, CFO Dale A. Sander purchased 20,000 shares of the business's stock in a transaction on Friday, December 16th. The stock was acquired at an average price of $2.60 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now owns 20,600 shares of the company's stock, valued at $53,560. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, CFO Dale A. Sander purchased 20,000 shares of the business's stock in a transaction on Friday, December 16th. The stock was acquired at an average price of $2.60 per share, for a total transaction of $52,000.00. Following the purchase, the chief financial officer now owns 20,600 shares of the company's stock, valued at $53,560. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Brady W. Dougan sold 239,538 shares of Humacyte stock in a transaction that occurred on Friday, December 16th. The stock was sold at an average price of $2.53, for a total transaction of $606,031.14. Following the transaction, the director now directly owns 17,990,736 shares in the company, valued at approximately $45,516,562.08. The disclosure for this sale can be found here. In the last quarter, insiders sold 939,268 shares of company stock worth $2,551,541. Insiders own 25.00% of the company's stock.

Hedge Funds Weigh In On Humacyte

Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Humacyte by 107.3% during the 1st quarter. Vanguard Group Inc. now owns 2,422,020 shares of the company's stock worth $17,099,000 after buying an additional 1,253,788 shares in the last quarter. BlackRock Inc. lifted its position in shares of Humacyte by 12.6% during the 1st quarter. BlackRock Inc. now owns 1,577,919 shares of the company's stock worth $11,140,000 after buying an additional 176,846 shares in the last quarter. Prescott General Partners LLC lifted its position in shares of Humacyte by 681.4% during the 1st quarter. Prescott General Partners LLC now owns 625,100 shares of the company's stock worth $4,413,000 after buying an additional 545,100 shares in the last quarter. State Street Corp raised its holdings in shares of Humacyte by 73.3% in the 2nd quarter. State Street Corp now owns 418,042 shares of the company's stock worth $1,342,000 after purchasing an additional 176,839 shares during the period. Finally, Millennium Management LLC raised its holdings in shares of Humacyte by 40.6% in the 2nd quarter. Millennium Management LLC now owns 398,765 shares of the company's stock worth $1,280,000 after purchasing an additional 115,192 shares during the period. Institutional investors own 13.05% of the company's stock.

About Humacyte

(Get Rating)

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs).

Read More

• Get a free copy of the StockNews.com research report on Humacyte (HUMA)
• Is There a Prize in Store for Kellogg Shareholders?
• Will AMC's Troubles Affect Its Landlord, EPR Properties?
• General Mills Retreats To More Attractive Territory
• Will Tesla Shares Rally If Musk Steps Down From Twitter?
• 5 Down But Not Out Stocks To Watch For 2023

Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.